LT position PART 1 Portfolio Positions acquired: $RNA $DAWN $SLNO $NARI $BPMC $MYOV base:0x9bba915f036158582c20b51113b925f243a1a1a1 $KRTX $HZNP $PRVB $ISEE $BLU $CTIC $FSTX $ICVX $LVGO $STML base:0x4e6c9f48f73e54ee5f3ab7e2992b2d733d0d0b07 $CMRX $RLYP $ITCI $KVUE Tech positions: In order $AMZN $META $NVDA $MSFT $SOFI $GOOGL $RDDT $MELI $APP $RKLB $INTC $IREN $NBIS $CRDO $AAOI $BE $AXON $MDB Biotech positions: $VKTX $CYTK $ARDX $HROW $MDGL $CRVS $ABVX $TMDX $RVMD $NKTR $CELC $AVR

BREAKING: Louisiana Governor Jeff Landry has declared a state of emergency in Louisiana as diesel prices rise to record levels during peak harvest season. Landry issued an executive order temporarily allowing dyed diesel, typically reserved for off-road vehicles, to be used in certain highway vehicles.

$AMZN and $GOOG are now investing in space.... Both companies have unlimited cash, unlimited resources and nothing is going to stop them....

$META will raise funds & increase CapEx significantly as Zuck just said on a podcast that he thinks the way to get to ASI is to brute force it with more compute. He said they want to get there and that compute is the way. He is signaling you exactly what $META is going to do.

Treasury 30-Year Yield has officially surpassed 5.5% for the first time since 2004

Have a great weekend everyone!

$VKTX Read the full post **“Number two most widely used bear theories on X: ‘LLY dominates obesity.’ ‘No room for late entrants.’ Both are null thesis. See the picture below Look at statins — the classic example. One drug dominated, but multiple late entrants still became blockbusters over time. The market wasn’t ‘crowded,’ it was stratified. Clinical strength determined winners, not timing. Obesity will behave like Statins: the best drugs take share, late entrants with superior drug profiles still become multi-billion franchises. Here's a classic snapshot of Statins usage and blockbuster status over time. There were roughly 5+ statins approved over time. Here's the timeline. 1) Lovastatin was approved in 1987 (Merck) 2) Pravastatin was approved in 1987 (Bristol-Myers) 3) Simvastatin was approved in 1991 (Merck) 4) Lipitor was approved in 1997 (Pfizer). Ten years after the first statin was approved and became the most successful drug for Pfizer even it came to the market so late. 5) Crestor was approved in 2003 (AstraZeneca). It became another blockbuster drug despite getting to the market after so many drugs already competing for the same crowded space.

$IOVA Locked in strong gains over $10+ with stock accumulation over a buck on dips. For a year this stock was criticized as a cult play, but the comeback proved the bears wrong. Your conviction and DD matter more than anyone’s commentary. Follow your thesis, not the chatter.

$IOVA Just from technical perspectives- Chart is setting up for another breakout over $12.4 pivot point. Stock has been super resilient irrespective of how biotech sector has performed lately and it has been in a continued uptrend regardless. Amazing strength. Just look at the chart.

$MRNA Shorts keep getting run over. Every dip turns into a squeeze. This is the best short squeeze I had recently seen. Good for longs.

Classic X behavior — my picks are legit, yours are pumps. Double standards everywhere. They spam their tickers nonstop but call everyone else pumpers.

$VKTX one bear thesis used over and over again "sector is crowded." Crowded? There’s only $LLY with a real obesity franchise on the market. $NVO isn’t even in the game — they were desperate enough to chase Metsera. If $NVO drugs were truly competitive, the stock wouldn’t be sitting near multi‑year lows. Calling this sector ‘crowded’ is just a childish bear thesis.

TRUMP: WILL BE MEETING WITH XI AGAIN IN NOVEMBER, IN CHINA, AND THEN AT G20 IN DECEMBER, IN MIAMI, FLORIDA TRUMP: MUCH HAS BEEN, AND WILL BE, ACCOMPLISHED

Added to $AVGO position

$CRDO Trimmed some of my position above $210. Another pullback opportunity win. 🎯 Mentioned previously that the stock had a strong support area around $160, and since then we’ve seen a nice bounce from that zone. ⬇️⬇️

$XBI Big Pharma does have the financial capacity to pursue $10–12B, $15–20B, and even larger acquisitions. The more important question is whether the asset is strategically important enough and sufficiently de-risked to justify that price. Some big acquisitions in the past has backfired. Or we see mid size deals in near future

$ABVX “Good support around $90. A breakdown puts $80 as the next support zone. The buyout thesis many chased all year hasn’t materialized yet. I guess market still concerned about that cancer scare with that initial drop in stock price down to $70's. Let's see how this story turns out to be in near term future.

One more time oil futures decline on hopes US-Iran deal. This is ongoing since Q1, and we are almost into Q4.

$SPY $QQQ Unbelievable how many times the market has to go through this nonsense. Deal or no deal. Tariffs ruled volatility in 2025, and this year it’s been Iran war headlines, oil spikes, yields, and Fed‑driven swings. Perfect setup for anyone playing both sides with better information than the rest of us.

$META Muse unstoppable